Efficacy & Tolerability

Many placebo-controlled studies have been conducted investigating the efficacy of Creon® in patients with Pancreatic Exocrine Insufficiency
(PEI).1-3  The data demonstrate that Creon® treats the symptoms of PEI and improves the nutritional status of patients with PEI and:

In all associated diseases, Creon® has been shown to:

  • increase fat absorption and reduce steatorrhoea
  • reduce stool frequency
  • improve stool consistency
  • be well tolerated

Creon® can achieve such improvements in patients with PEI because it has been developed to mimic the normal physiological conditions of a healthy pancreas in levels of dosing and timing.4


A review of data from 15,000 patients with PEI and cystic fibrosis, chronic pancreatitis or pancreatic cancer found that side effects were present in < 1% of patients. The most commonly reported adverse reactions were gastrointestinal disorders which are mainly associated with underlying disease. According to the Creon® SPC, similar or lower incidences compared to placebo were reported for abdominal pain and diarrhoea.1-3,5


  1. Creon Micro Summary of Product Characteristics. November 2016.
  2. Creon 10000 Capsules Summary of Product Characteristics. January 2017.
  3. Creon 25000 Capsules Summary of Product Characteristics. January 2017.
  4. Domínguez-Muñoz JE et al. Adv Med Sci. 2011; 56(1): 1-5.
  5. Imrie CW et al. Aliment Pharmacol Ther. 2010; 32(Suppl1): 1-25.
  6. Toouli J et al. Med J Aust. 2010; 193(8): 461-7.

Guideline Recommendation

… the cornerstone of therapy for PEI is replacement of pancreatic enzymes to allow for efficient digestion and nutrient absorption.4

Watch how Creon®'s unique mode of action delivers the right dose

Follow the Link  Watch now

You will now leave the Creon patient website and go to the Creon Track site where you can join the Creon Track patient support programme

Would you like to proceed to the Creon Track registration website?